X0609 4 2026-10-01 0001645469 Monopar Therapeutics MNPR 0001235470 STARR CHRISTOPHER M false 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 1 1 Common Stock 2026-10-01 4 M 0 8400 0.005 A 13573 D Common Stock 2026-10-01 4 S 0 4631 78.09 D 8942 D Common Stock 2026-10-01 4 S 0 2970 78.82 D 5972 D Common Stock 2026-10-01 4 S 0 799 79.67 D 5173 D Common Stock 9880 I See Footnote Stock Option 0.005 2026-10-01 4 M 0 8400 0 D 2027-02-19 Common Stock 8400 8400 D This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter. Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. /s/ Quan Vu, Attorney-in-fact 2026-10-05